Abstract: The invention relates to a novel bacterial strain deposited with the CNCM under number 1-4969. This strain has properties that are useful in the treatment of respiratory disorders. The invention also relates to compositions and uses of said strain.

Abstract: The invention provides a composition for use in therapy of lactose intolerance or conditions arising from lactase deficiency, wherein the composition is a non-dairy solid dosage form comprising: (a) a lactase; and (b) one or more lactase-producing and/or lactase containing microorganisms selected from Lactobacillus delbrueckii ssp bulgaricus and Streptococcus thermophilus; wherein the lactase (a) is other than a lactase derived from the said one or more microorganisms (b); and wherein the one or more lactase-producing and/or lactase-containing microorganisms (b) are in dried form. Also provided are uncoated capsule and tablet compositions containing the lactase and the lactase-producing and/or lactase-containing microorganisms.

Abstract: The present invention relates to at least one probiotic strain of Lactobacillus for use in a subject for the prevention and/or treatment of celiac disease autoimmunity (CDA), or for use in the prevention and/or treatment of celiac disease (CD). A preferred composition for use according to the invention is a composition comprising a combination of Lactobacillus paracasei and Lactobacillus plantarum, especially L. paracasei 8700:2 (DSM 13434) in combination with L. plantarum HEAL 9 (DSM 15312).

Abstract: The invention relates in one aspect to a pharmaceutical composition comprising a nucleic acid delivery vehicle for delivering a deliverable nucleic acid into a bacterial cell, wherein the delivery vehicle comprises a deliverable nucleic acid packaged into one or more bacteriophage coat proteins, and wherein the delivery vehicle is capable of infecting the bacterial cell to introduce the deliverable nucleic acid into the cell, following which the deliverable nucleic acid is capable of forming a plasmid in the cell and being transmitted to one or more different bacterial cells by conjugation and not by infection. Compositions including a pharmaceutical composition comprising the delivery vehicle, and methods involving use or manufacture of the delivery vehicle, are also disclosed.

Abstract: The present invention provides an anticancer agent containing the following (1) and (2): (1) HVJ-E (hemagglutinating virus of Japan envelope), (2) an inhibitor of an immune checkpoint protein.

Abstract: This invention relates generally to viral vectors and viral particles based on Anelloviruses, which can be used to deliver an agent (e.g., an exogenous effector or an endogenous effector, e.g., a therapeutic effector) to a cell (e.g., a cell in a subject to be treated therapeutically). Described herein are anellosomes, anellovectors, and compositions and uses thereof.

Abstract: The present invention relates to compositions comprising one or more compounds and/or extracts which induce, promote and/or improve production/release/delivery/excretion of hyaluronic acid from and/or in the cornea, and methods of using the compositions to treat the eye.

Abstract: A method for stimulating or enhancing the immune system with a composition that includes a Eurycoma longifolia aqueous extract. Also provided is a method for reducing the risk of infectious disease by administering the composition. Further disclosed is a method for treating an individual with a Eurycoma longifolia aqueous extract to increase the number of T-cells, improve Scoring of Immunological Vigor, lower immunological age, reduce fatigue, or alleviate or reduce stress.

Abstract: The present application relates to a compositions and methods comprising or expressing a MOMO30 protein derived from Momordica balsamina. The MOMO30 protein is about 30 kDa in size, binds coronavirus S protein, is stable after being autoclaved at 120° C. for 30 min, resists proteolytic cleavage by trypsin, exhibits mannose-sensitive binding to coronavirus spike (S) protein, exhibits hemagglutinin and chitinase activity, is capable of activating and stimulating T cell proliferation, is capable of preventing infection by a coronavirus or alleviating symptoms in coronavirus infected patients and comprises the amino acid sequence of SEQ ID NO: 1. The MOMO30 protein and/or a nucleic acid encoding the same may be used in methods for preventing or treating viral infections by coronaviruses and others.

Abstract: A herbal composition with significant potent therapeutic effects for treating neurodegenerative diseases by targeting both amyloid-? (A?) and tau-associated neurofibrillary tangles (NFTs) is provided.

Abstract: A method for promoting weight management in a mammal is provided, comprising administering to the mammal a weight loss agent and a mitochondria enhancing agent. Compositions for weight management are also provided.

Abstract: The present invention relates to a pharmaceutical composition. The pharmaceutical composition is the organic phase of raw garlic (Allium sativum, all species) or water extraction to provide novel cancer treatments of multiple malignant neoplasms, infectious diseases and Type 2 diabetes. The effective formulation of OPRGE is either liquid or dry powder of OPRGE; the effective routes of administration is intravenous (IV) for infectious diseases and diabetes; the effective routes of administration is intravenous (IV) or intraperitoneal (IP) or intratumoral infusions for malignant neoplasms. The patent application consistent of OPRGE extraction methods, mode of administration of OPRGE and clinical indications.

Abstract: The present invention provides methods for treating or ameliorating primary progressive multiple sclerosis (PPMS) or secondary progressive multiple sclerosis (SPMS) and related symptoms by administering or implanting a depot formulation comprising glatiramer salts, such as glatiramer acetate (GA).

Abstract: The present invention provides methods for treating moderate-to-severe or severe atopic dermatitis (AD). The methods of the present invention comprise administering to a subject in need thereof one or more doses of an interleukin-4 receptor (IL-4R) inhibitor such as an anti-IL-4R antibody. In certain embodiments, the methods of the present invention are used to treat severe AD in a patient whose disease is not controlled with systemic therapy (e.g., cyclosporine A) or when such therapy is inadvisable.

Abstract: Compositions and methods for the treatment of Sjogren's syndrome (SS) and SS-related symptoms in human subjects are described. The compositions comprise synthetic peptides based on the sequence of CDR1 of an anti-DNA monoclonal antibody.

Abstract: Provided are nine multi-target polypeptides of an opioid and a neuropeptide FF receptor, where an amino acid is replaced on the basis of opioid peptide biphalin- and NPFF-based chimeric peptide BN-9, and acquired are the multi-target polypeptides capable of concurrently activating various opioid and NPFF system receptors.

Abstract: Disclosed herein, inter alia, are FOXM1 modulators and methods for modulating the activity of androgen receptors in neuronal cells to treat various diseases, such as spinal-bulbar muscular atrophy, amyotrophic lateral sclerosis, and Alzheimer's disease.

Abstract: Disclosed herein are compositions comprising immunomodulatory and oncolytic eubacterial minicells, and the use of the composition in immunomodulatory therapies for cancer. In some embodiments, the minicells are used in combination of immune checkpoint inhibitors in treating cancer.

Abstract: The present invention relates to a pharmaceutical composition for inhibiting tumor development, which comprises Tamm-Horsfall glycoprotein, native or pegylated and a pharmacologically acceptable excipient, therapeutic methods and uses.

Abstract: The invention provides for methods for treating an inflammatory disease of the digestive system in a subject by administering a trefoil family molecule. The invention provides for methods for treating a digestive system cancer in a subject by administering a trefoil family molecule. The invention provides for methods for cell proliferation in a subject by administering a trefoil family molecule.

Abstract: Provided is a composition comprising a peptide comprising amino acids and/or amino acid analogs comprising a continuous sequence of a sclerostin fragment comprising Tyr43 or Tyr213. Also provided is a composition comprising a peptide comprising less than about 75 amino acids and/or amino acid analogs including an amino acid or amino acid analog capable of being sulfated, where the composition is capable of inhibiting sclerostin binding to an LRP. Further provided is a composition comprising a peptide comprising less than about 75 amino acids and/or amino acid analogs including an amino acid or amino acid analog capable of being post-translationally sulfated, where the composition is capable of inhibiting binding of a protein ligand comprising a sulfation site to its binding partner. Also provided are methods of using the compositions.

Abstract: A C—C chemokine receptor 3 (CCR3) peptide analog that exhibits biased antagonism by binding to and inhibiting ligand-mediated signaling and chemotaxis while promoting the internalization and degradation of CCR3 is provided as is a method of using the peptide analog to treat, prevent, or ameliorate one or more symptoms of an eosinophil- or CCR3-mediated disease or condition.

Abstract: The present disclosure relates to a composition for the release of the bioactive substance comprising: sucrose acetate isobutyrate dissolved in an ionic liquid and an additive selected from the list consisting of: chitin, silk fibroin, cellulose, alginate, chitosan, gellan gum, dextrin, collagen, guar gum, carregeenan, heparin, kefiran, or mixtures thereof. By taking advantage of the properties of an ionic liquid (IL), in particular 1-butyl-imidazolium acetate (BMIMAc), it was possible to achieve a good dissolution of SAIB, which combined with chitin and/or silk, natural polymers, allows the development of the structures with different shape and sizes.

Abstract: The present invention relates to solid compositions for oral administration comprising (i) a GLP-1 derivative and the SGLT2 inhibitor dapagliflozin or (ii) a GLP-1 derivative and a salt of NAC in combination with an SGLT2 inhibitor.

Abstract: The present invention provides novel uses and methods for T cell based immunotherapies. Specifically, the invention relates to novel ligands, targets and nucleic acids and vectors encoding said targets that are useful for modulating T cell responses.

Abstract: The purpose of the present invention is to provide an agent for improving intestinal flora which can increase the number of beneficial bacteria such as lactic acid bacteria and Bifidobacterium to improve intestinal flora by using an enzyme. A protease consisting of a polypeptide having an amino acid sequence shown in SEQ ID NO: 1 can increase beneficial bacteria such as lactic acid bacteria and Bifidobacterium in intestines to exert an excellent effect of improving intestinal flora.

Abstract: The present invention describes vaccine compositions for treatment and/or prevention against sea lice infestation in salmon. The present invention further describes nucleic acids, host cells, vectors and methods of using said vaccine for the prevention and/or treatment of sea lice infestation in salmon.

Abstract: Provided herein are compositions and methods for the induction and/or proliferation of CD8+ T-cells. The disclosure also provides methods of treatment of diseases that can be treated by the induction and/or proliferation of CD8+ T-cells.

Abstract: A vaccine platform using a Yersinia pestis mutant synthesizing an adjuvant form lipid A (monophosphoryl lipid A, MPLA) for the increased biogenesis of bacterial outer membrane vesicles (OMVs). To enhance the immunogenicity of the OMVs, an Asd-based balanced-lethal host-vector system was constructed to oversynthesize the LcrV antigen of Y. pestis, raise the amounts of LcrV enclosed in OMVs by Type II secretion system, and eliminate harmful factors like plasminogen activator (Pla) and murine toxin from the OMVs. Vaccination with OMVs containing MPLA and increased amounts of LcrV with diminished toxicity afforded complete protection in mice against subcutaneous challenge and intranasal challenge and was significantly superior to that resulting from vaccination with LcrV/alhydrogel. Additionally, the Yersinia OMV can be used as a platform to deliver the heterologous antigens of Bacillus anthraces.

Abstract: Methods of immunizing older adult subjects against Streptococcus pneumoniae infection are provided. Provided methods comprise immunization of naïve adult subjects with a conjugated pneumococcal polysaccharide vaccine. Optionally, initial immunization may be followed by additional immunization doses comprising conjugated pneumococcal polysaccharide vaccine or unconjugated pneumococcal polysaccharide vaccine composition.

Abstract: The present invention pertains to a vaccine comprising an IgM protease antigen of Streptococcus suis, for use in a method for protecting piglets having maternally derived anti-Streptococcus suis antibodies against Streptococcus suis, by administering the vaccine to the piglets at an age of at most 28 days, preferably before the piglets are weaned.

Abstract: The present invention relates to immunogenic compositions comprising an immunogenic polypeptide from Haemophilus influenzae or an immunogenic fragment thereof and/or an immunogenic polypeptide from Moraxella catarrhalis or an immunogenic fragment thereof, for use in the treatment or prevention of a recurrence of an acute exacerbation of chronic obstructive pulmonary disease (AECOPD) resulting from a bacterial infection in a subject.

Abstract: This application discloses methods, compositions, and articles of manufacture for using NDV-induced serum to treat non-human mammals, including dogs, displaying severe neurological symptoms of advanced canine distemper virus (CDV) infection. An off-the-shelf chicken vaccine is injected into two or more healthy mammals, of the same species as the sick animal, to provoke an immune response. After allowing several hours for the immune response to develop, blood is drawn from the healthy mammals and centrifuged to obtain serum. This “NDV-induced serum” can be injected into a mammal of the same species displaying severe neurological symptoms of advanced CDV infection on a prescribed schedule to bolster the sick animal's immune responses, preferably leading to clearance of the virus without the need for a spinal tap, which is the standard treatment for advanced CDV infection in mammals.

Abstract: Embodiments of the disclosure concern methods of identifying whether or not antigens from a particular pathogen are immunogenic, including the order of their immunogenicity. Other embodiments concern correlations between attributes of T cells and their clinical efficacy, such as mathematical representations thereof.

Abstract: The invention provides methods and compositions for eliciting broad immune responses. The methods employ nucleic acid vaccines that encodes highly conserved elements from a virus.

Abstract: The present invention provides methods for inducing an immune response to a pathogen in neonatal mammals. In particular, the present invention provides methods for inducing an immune response to a pathogen in a neonatal mammal comprising administering to the neonatal mammal a composition comprising a fusion protein between interleukin-4 (IL-4) and a first antigen of the pathogen.

Abstract: The present invention provides new multivalent vaccines for felines. The present invention also provides methods of making and using the multivalent vaccines alone or in combinations with other protective agents.

Abstract: This invention generally relates to cationic oil-in-water emulsions that contain high concentrations of cationic lipids and have a defined oil:lipid ratio. The cationic lipid can interact with the negatively charged molecule thereby anchoring the molecule to the emulsion particles. The cationic emulsions described herein are useful for delivering negatively charged molecules, such as nucleic acid molecules to cells, and for formulating nucleic acid-based vaccines.

Abstract: Described is a combination therapy of (i) a multifunctional antibody having specificity for CD30 and CD16A and (ii) an anti-PD-1 antibody for the treatment of a tumor, in particular Hodgkin lymphoma.

Abstract: The invention provides an aqueous formulation comprising water and a protein, and methods of making the same. The aqueous formulation of the invention may be a high protein formulation and/or may have low levels of conductivity resulting from the low levels of ionic excipients. Also included in the invention are formulations comprising water and proteins having low osmolality.

Abstract: Provided is a novel additive for an orally disintegrating tablet providing quick disintegrability and tablet hardness to the orally disintegrating tablet, and a producing method therefor. According to an embodiment of the present invention, there is provided an additive for an orally disintegrating tablet characterized by including D-mannitol, low-substituted hydroxypropyl cellulose (however, excluding the low-substituted hydroxypropyl cellulose having a mean particle size of 20 ?m or less and a substitution degree of hydroxypropoxy groups of 11%, a mean particle size of 45 ?m or less and a substitution degree of hydroxypropoxy groups of 14%, and a mean particle size of 45 ?m or less and a substitution degree of hydroxypropoxy groups of 11% and a 90% cumulated particle size of 100 ?m or less), crospovidone, and microcrystalline cellulose, wherein the low-substituted hydroxypropyl cellulose and the crospovidone are included in a ratio of 5:4.

Abstract: The present disclosure provides inter alia compositions that comprise therapeutic agents (e.g., live attenuated viral antigens, therapeutic proteins, etc.) and a lipid component. The lipid component may comprise or consist of different types of lipid or lipids as described herein. In some embodiments the therapeutic agents are thermolabile. The present disclosure also provides methods for preparing compositions, including the aforementioned compositions (e.g., melt methods and spray injection methods among others).

Abstract: The present disclosure provides compositions and methods useful for treating viral infections. As described herein, the compositions and methods are based on the development of immunogenic compositions that include an inactivated virus in combination with a non-ionic surfactant vesicle (NISV). In certain embodiments at least a portion of the antigen present in the composition is physically associated with the NISV. In certain embodiments the compositions are lyophilized and subsequently rehydrated after a period of storage. In certain embodiments the rehydrated compositions exhibit greater potency as compared to otherwise equivalent compositions that lack the NISV. In certain embodiments the lyophilized compositions are stored at temperatures in excess of 8° C. prior to rehydration. In certain embodiments, the rehydrated compositions exhibit greater potency as compared to otherwise equivalent compositions that lack the NISV and that were also stored at temperatures in excess of 8° C. prior to rehydration.

Abstract: This invention provides compositions for controlled localized release of one or more drugs within a subject. More particularly, described herein are compositions comprising a hydrophobic water-insoluble polymer, a low molecular weight biocompatible glycol, and one or more drugs. The compositions described herein may also optionally include a di-block copolymer and/or a swelling agent.

Abstract: The invention is related to insulin compositions with a high content of zinc atoms per six molecules of acylated insulin. The insulin is an acylated insulin and may be mixed with a further insulin analogue such as the rapid acting insulin Asp B28 human insulin.

Abstract: The subject disclosure is directed to techniques for enhancing the selectivity and efficacy of therapeutic polymers against a broad spectrum of pathogens and cancer cell lines. According to an embodiment, a method is provided that comprises forming a therapeutic polymer based on polymerization of a plurality of therapeutic monomers, wherein the therapeutic polymer provides a therapeutic functionality. The method further comprises attaching biotin to the therapeutic polymer, resulting in a biotin-functionalized therapeutic polymer, wherein the biotin-functionalized therapeutic polymer provides greater therapeutic efficacy relative to the therapeutic polymer.

Abstract: The present invention relates to an antibody drug conjugate using a bispecific antibody and its use. The antibody drug conjugate of the present invention can easily form a conjugate of an antibody and a drug without a multistep synthetic process though binding of a conjugate of a bivalent cotinine-peptide and a drug, and an anti-cotinine single chain variable fragment. In addition, the antibody drug conjugate can effectively deliver a drug to a target to which the antibody binds specifically, and can enhance a half-life of a drug in the body, thereby improving a therapeutic effect.

Abstract: The present invention relates to compositions and methods for improving the safety of blood-brain barrier receptor-mediated blood-brain barrier transport.

Abstract: Provided are antibody-drug conjugates (ADCs) that bind to, and kill MET expressing tumor cells, and that are effective in treating MET expressing cancers. Also provided are novel compounds and methods of conjugating MET antibodies to generate such ADCs.

Abstract: In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and at least two active agents. In preferred embodiments, the linker comprises a peptide sequence of a plurality of amino acids, and at least two of the active agents are covalently coupled to side chains of the amino acids. The antibody-drug conjugate may comprise a self-immolative group, preferably two-self-immolative groups. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.